Search results
Results From The WOW.Com Content Network
340B DSH hospitals provide nearly twice as much care as non-340B hospitals – 41.9 percent versus 22.8 percent – to Medicaid beneficiaries and low-income Medicare patients. 340B hospitals provide 40 percent more uncompensated care as a percent of total patient care costs than non-340B hospitals – $24.6 billion to $17.5 billion.
The 340B Drug Pricing Program, administered by the Office of Pharmacy Affairs, resulted from enactment of Public Law 102-585, the Veterans Health Care Act of 1992, which is codified as Section 340B of the Public Health Service Act. Section 340B limits the cost of covered outpatient drugs to more than 18,000 eligible entities including ten types ...
In 2010, the Patient Protection and Affordable Care Act, commonly known as Obamacare or the Affordable Care Act, was created. The goal was to increase the number of people who had healthcare in the United States and reduce the impact that individual healthcare spending had on households, especially since many Americans had lost their health ...
The 340B drug pricing program, originally intended to help low-income and uninsured patients, has been exploited by special interests for profit, resulting in higher drug prices, taxes, and ...
The Medicaid Drug Rebate Program has undergone a number of changes since its inception. For example, Section 606 of the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (BBRA) amended Section 1927(a)(1) allowing states to have the option of different rebate effective dates. This section states that agreements to the rebate ...
for the particular submission, required under this section. Three copies of the application are required: An archival copy, a review copy, and a field copy. An application for a new chemical entity will generally contain an application form, an index, a summary, five or six
Patient safety work product includes any data, reports, records, memoranda, analyses (such as root cause analyses), or written or oral statements (or copies of any of this material), which are assembled or developed by a provider for reporting to a PSO and are reported to a PSO; or are developed by a patient safety organization for the conduct ...
The bill also places a burden on any comparative effectiveness program to take into account factors contributing to differences in the treatment response, or the treatment preferences of patients. This would include patient-reported outcomes, genomics, personalized medicine, the unique needs of health disparity populations (sic.), and indirect ...